08:38 AM EDT, 03/31/2025 (MT Newswires) -- Corcept Therapeutics ( CORT ) said Monday its phase 3 trial of relacorilant plus nab-paclitaxel to treat a type of ovarian cancer met its primary goal, sending shares up more than 90% in recent premarket trading activity.

The company said the study showed a 30% reduction in the risk of disease progression for patients treated with relacorilant and nab-paclitaxel compared to those receiving nab-paclitaxel alone.

The drug developer said the median progression-free survival assessed by blinded independent central review was 6.5 months for the combination therapy group, compared to 5.5 months for those on nab-paclitaxel alone.

In an interim evaluation of overall survival, the company said the combination therapy group showed a significant improvement, with a median overall survival of 16 months versus 11.5 months for the control group.

It added the combination therapy was well-tolerated, with no increased side effect burden.

Corcept said it plans to submit a new drug application for the therapy in Q3.